DK2120923T3 - Anvendelse af substituerede pyranonsyrederivater til behandling af det metaboliske syndrom - Google Patents

Anvendelse af substituerede pyranonsyrederivater til behandling af det metaboliske syndrom

Info

Publication number: DK2120923T3
Authority: DK; Denmark
Prior art keywords: pyranonic; treat; substituted; acid derivatives; metabolic syndrome
Prior art date: 2007-01-16

Application number

DK08700981.7T

Other languages

English (en)

Inventor

Harm Brummerhop

Siegfried Stengelin

Hubert Heuer

Andreas Herling

Thomas Klabunde

Dieter Kadereit

Matthias Urmann

Susanne Kilp

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-01-16

Filing date

2008-01-04

Publication date

2012-10-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39232744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2120923(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-01-04 Application filed by Sanofi Sa filed Critical Sanofi Sa

2012-10-29 Application granted granted Critical

2012-10-29 Publication of DK2120923T3 publication Critical patent/DK2120923T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Hematology (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Virology (AREA)
Psychiatry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Immunology (AREA)
Child & Adolescent Psychology (AREA)

DK08700981.7T 2007-01-16 2008-01-04 Anvendelse af substituerede pyranonsyrederivater til behandling af det metaboliske syndrom DK2120923T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE102007002260A DE102007002260A1 (de)	2007-01-16	2007-01-16	Verwendung von substituierten Pyranonsäurederivaten zur Herstellung von Medikamenten zur Behandlung des Metabolischen Syndroms
PCT/EP2008/000029 WO2008086949A1 (de)	2007-01-16	2008-01-04	Verwendung von substituierten pyranonsäurederivaten zur behandlung des metabolischen syndroms

Publications (1)

Publication Number	Publication Date
DK2120923T3 true DK2120923T3 (da)	2012-10-29

Family

ID=39232744

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK08700981.7T DK2120923T3 (da)	2007-01-16	2008-01-04	Anvendelse af substituerede pyranonsyrederivater til behandling af det metaboliske syndrom

Country Status (31)

Country	Link
US (1)	US8748483B2 (da)
EP (1)	EP2120923B1 (da)
JP (1)	JP2010515765A (da)
KR (1)	KR20090110834A (da)
CN (1)	CN101600427A (da)
AR (1)	AR064899A1 (da)
AU (1)	AU2008207170A1 (da)
BR (1)	BRPI0806661A2 (da)
CA (1)	CA2675442A1 (da)
CL (1)	CL2008000110A1 (da)
CR (1)	CR10850A (da)
CY (1)	CY1113148T1 (da)
DE (1)	DE102007002260A1 (da)
DK (1)	DK2120923T3 (da)
DO (1)	DOP2009000177A (da)
EC (1)	ECSP099518A (da)
ES (1)	ES2390513T3 (da)
HR (1)	HRP20120763T1 (da)
IL (1)	IL199829A0 (da)
MA (1)	MA31094B1 (da)
MX (1)	MX2009006913A (da)
PE (1)	PE20081700A1 (da)
PL (1)	PL2120923T3 (da)
PT (1)	PT2120923E (da)
RS (1)	RS52494B (da)
RU (1)	RU2009131058A (da)
SI (1)	SI2120923T1 (da)
TN (1)	TN2009000275A1 (da)
TW (1)	TW200836716A (da)
UY (1)	UY30871A1 (da)
WO (1)	WO2008086949A1 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de)	2010-06-18	2011-12-22	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2931715B1 (de) *	2012-12-13	2016-12-21	Merck Patent GmbH	3-hydroxy-4-oxo-4h-pyran- oder 3-hydroxy-4-oxo-1,4-dihydro-pyridin-derivate als protein-adhäsive wirkstoffe
JP6338276B2 (ja) *	2014-07-10	2018-06-06	学校法人神奈川大学	抗癌剤
IL300478A (en)	2020-08-12	2023-04-01	Spruce Biosciences Inc	Methods and preparations for the treatment of polycystic ovary syndrome

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3152148A (en)	1963-01-03	1964-10-06	Dow Chemical Co	Preparation of comenic and pyromeconic acids
EP0006749B1 (en)	1978-06-26	1984-02-22	Measurex Corporation	Method and apparatus for measuring gas, including standardisation
JPS59125644A (ja)	1982-12-29	1984-07-20	Fujitsu Ltd	半導体装置
US4603144A (en)	1984-08-16	1986-07-29	G. D. Searle & Co.	Kojic acid ether-ester derivatives
GB8615041D0 (en) *	1986-06-20	1986-07-23	Silver J	Pharmaceutical compositions
DE3728602A1 (de)	1987-08-27	1989-03-09	Bayer Ag	Faserverstaerktes polyphenylensulfid
DE3728924A1 (de)	1987-08-29	1989-03-09	Bayer Ag	Flammwidrige, thermoplastische formmassen auf basis von polycarbonat, polyalkylenterephthalat, pfropfcopolymerisat, fluoriertem polyolefin und phosphorverbindung
DE3729586A1 (de)	1987-09-04	1989-03-16	Ant Nachrichtentech	Verfahren zum ausgleichen von durch den doppler-effekt hervorgerufenen laufzeit-verschiebungen der bursts in einem tdma-rahmen sowie anordnung
CA2007414C (en)	1989-04-26	1994-10-25	Clayton James Bennett Iii	Method for manipulating elements within a structured document using active intent interpretations
FR2663336B1 (fr)	1990-06-18	1992-09-04	Adir	Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH06271500A (ja) *	1993-03-23	1994-09-27	Noguchi Kenkyusho	コマン酸の製造法
DE19530298C2 (de) *	1995-08-17	1999-07-22	Woerwag Pharma Gmbh	Verwendung von Orotsäure zur Prävention und Therapie des metabolischen Syndroms
CA2241567A1 (en)	1996-01-17	1997-07-24	Novo Nordisk A/S	Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
UA51716C2 (uk)	1996-07-08	2002-12-16	Авентіс Фармасьютікалз Продактс Інк.	Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
CA2264243C (en)	1996-08-30	2004-10-05	Novo Nordisk A/S	Glp-1 derivatives
CN1190434C (zh)	1996-12-31	2005-02-23	雷迪实验室有限公司	新的杂环化合物、其制备方法和含有它们的药物组合物及其在治疗糖尿病和相关疾病中的应用
DE19726167B4 (de)	1997-06-20	2008-01-24	Sanofi-Aventis Deutschland Gmbh	Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
JP2001510195A (ja)	1997-07-16	2001-07-31	ノボノルディスクアクティーゼルスカブ	縮合化１，２，４−チアジアジン誘導体、その調製及び使用
CO4970713A1 (es)	1997-09-19	2000-11-07	Sanofi Synthelabo	Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
US6221897B1 (en)	1998-06-10	2001-04-24	Aventis Pharma Deutschland Gmbh	Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de)	1998-10-02	2000-07-13	Aventis Pharma Gmbh	Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en)	1999-01-08	1999-02-24	Alizyme Therapeutics Ltd	Inhibitors
JP2002542245A (ja)	1999-04-16	2002-12-10	ノボノルディスクアクティーゼルスカブ	置換イミダゾール、それらの製造および使用
MXPA01010880A (es)	1999-04-28	2002-05-06	Aventis Pharma Gmbh	Derivados de acido diarilico como ligandos de receptor ppar.
EE200100558A (et)	1999-04-28	2002-12-16	Aventis Pharma Deutschland Gmbh	Triarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi raviotstarbeline kasutamine
WO2000066585A1 (en)	1999-04-30	2000-11-09	Neurogen Corporation	9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS
GB9911863D0 (en)	1999-05-21	1999-07-21	Knoll Ag	Therapeutic agents
CA2376919C (en)	1999-06-18	2008-11-04	Merck & Co., Inc.	Arylthiazolidinedione and aryloxazolidinedione derivatives
PT1204654E (pt)	1999-07-29	2003-11-28	Lilly Co Eli	Benzofurilpiperazinas agonistas do receptor 5-ht2c da serotonina
CA2383781A1 (en)	1999-09-01	2001-03-08	Aventis Pharma Deutschland Gmbh	Sulfonyl carboxamide derivatives, method for their production and their use as medicaments
PT1277736E (pt)	2000-04-28	2007-10-12	Asahi Kasei Pharma Corp	Novos compostos bicíclicos
BR0110638A (pt)	2000-05-11	2003-03-25	Bristol Myers Squibb Co	Análogos de tetraidroisoquinolina úteis como secretagogos de hormÈnio do crescimento
WO2001091752A1 (en)	2000-05-30	2001-12-06	Merck & Co., Inc.	Melanocortin receptor agonists
DE10033353A1 (de)	2000-07-08	2002-01-24	Aventis Pharma Gmbh	Breit einsetzbares Verfahren zur Identifizierung von Modulatoren von G-Protein gekoppelten Rezeptoren
FR2814678B1 (fr)	2000-10-04	2002-12-20	Aventis Pharma Sa	Association d'un antagoniste du recepteur cb1 et de sibutramine, les compositions pharmaceutiques les contenant et leur utilisation pour la traitement de l'obesite
IL156552A0 (en)	2000-12-21	2004-01-04	Aventis Pharma Gmbh	Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
JP4436129B2 (ja)	2001-08-31	2010-03-24	サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	ジアリールシクロアルキル誘導体、その製造法及びｐｐａｒ−活性剤としてのその使用
US6552073B1 (en)	2002-03-01	2003-04-22	Exonhit Therapeutics Sa	Compounds and methods of treating cell proliferative diseases
DE10227508A1 (de)	2002-06-19	2004-01-08	Aventis Pharma Deutschland Gmbh	Säuregruppen-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227507A1 (de)	2002-06-19	2004-01-08	Aventis Pharma Deutschland Gmbh	Kationisch substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10227506A1 (de)	2002-06-19	2004-01-08	Aventis Pharma Deutschland Gmbh	Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE10307004B3 (de)	2003-02-19	2004-08-05	Siemens Ag	Verfahren zur Steuerung einer Brennkraftmaschine mit einer Lambda-Regelung

2007
- 2007-01-16 DE DE102007002260A patent/DE102007002260A1/de not_active Withdrawn
2008
- 2008-01-04 RU RU2009131058/15A patent/RU2009131058A/ru unknown
- 2008-01-04 PT PT08700981T patent/PT2120923E/pt unknown
- 2008-01-04 AU AU2008207170A patent/AU2008207170A1/en not_active Abandoned
- 2008-01-04 RS RS20120437A patent/RS52494B/en unknown
- 2008-01-04 DK DK08700981.7T patent/DK2120923T3/da active
- 2008-01-04 EP EP08700981A patent/EP2120923B1/de active Active
- 2008-01-04 KR KR1020097014783A patent/KR20090110834A/ko not_active Application Discontinuation
- 2008-01-04 BR BRPI0806661-2A patent/BRPI0806661A2/pt not_active IP Right Cessation
- 2008-01-04 SI SI200830757T patent/SI2120923T1/sl unknown
- 2008-01-04 ES ES08700981T patent/ES2390513T3/es active Active
- 2008-01-04 JP JP2009545849A patent/JP2010515765A/ja not_active Withdrawn
- 2008-01-04 MX MX2009006913A patent/MX2009006913A/es not_active Application Discontinuation
- 2008-01-04 CA CA002675442A patent/CA2675442A1/en not_active Abandoned
- 2008-01-04 WO PCT/EP2008/000029 patent/WO2008086949A1/de active Application Filing
- 2008-01-04 PL PL08700981T patent/PL2120923T3/pl unknown
- 2008-01-04 CN CNA2008800023932A patent/CN101600427A/zh active Pending
- 2008-01-14 AR ARP080100165A patent/AR064899A1/es not_active Application Discontinuation
- 2008-01-14 TW TW097101284A patent/TW200836716A/zh unknown
- 2008-01-14 UY UY30871A patent/UY30871A1/es not_active Application Discontinuation
- 2008-01-14 PE PE2008000138A patent/PE20081700A1/es not_active Application Discontinuation
- 2008-01-15 CL CL200800110A patent/CL2008000110A1/es unknown
2009
- 2009-06-09 CR CR10850A patent/CR10850A/es not_active Application Discontinuation
- 2009-06-26 TN TNP2009000275A patent/TN2009000275A1/fr unknown
- 2009-07-13 DO DO2009000177A patent/DOP2009000177A/es unknown
- 2009-07-13 IL IL199829A patent/IL199829A0/en unknown
- 2009-07-14 MA MA32090A patent/MA31094B1/fr unknown
- 2009-07-15 EC EC2009009518A patent/ECSP099518A/es unknown
- 2009-07-16 US US12/504,198 patent/US8748483B2/en not_active Expired - Fee Related
2012
- 2012-09-26 HR HRP20120763AT patent/HRP20120763T1/hr unknown
- 2012-09-27 CY CY20121100882T patent/CY1113148T1/el unknown

Also Published As

Publication number	Publication date
EP2120923A1 (de)	2009-11-25
HRP20120763T1 (hr)	2012-10-31
US20100144862A1 (en)	2010-06-10
MA31094B1 (fr)	2010-01-04
AU2008207170A1 (en)	2008-07-24
WO2008086949A1 (de)	2008-07-24
DE102007002260A1 (de)	2008-07-31
KR20090110834A (ko)	2009-10-22
SI2120923T1 (sl)	2012-10-30
TN2009000275A1 (en)	2010-10-18
ES2390513T3 (es)	2012-11-13
JP2010515765A (ja)	2010-05-13
PL2120923T3 (pl)	2012-12-31
ECSP099518A (es)	2009-08-28
CA2675442A1 (en)	2008-07-24
TW200836716A (en)	2008-09-16
US8748483B2 (en)	2014-06-10
BRPI0806661A2 (pt)	2011-09-06
CY1113148T1 (el)	2016-04-13
RU2009131058A (ru)	2011-02-27
DOP2009000177A (es)	2009-08-15
IL199829A0 (en)	2010-04-15
AR064899A1 (es)	2009-05-06
UY30871A1 (es)	2008-09-02
EP2120923B1 (de)	2012-07-18
PE20081700A1 (es)	2009-01-08
MX2009006913A (es)	2009-08-12
PT2120923E (pt)	2012-08-31
CL2008000110A1 (es)	2008-05-16
CN101600427A (zh)	2009-12-09
CR10850A (es)	2009-10-16
RS52494B (en)	2013-02-28

Publication	Publication Date	Title
DK2120923T3 (da)	2012-10-29	Anvendelse af substituerede pyranonsyrederivater til behandling af det metaboliske syndrom
DK2178840T3 (da)	2012-03-26	Azabiphenylaminobenzoesyre-derivater som dhodh-hæmmere
PL2807926T3 (pl)	2021-05-31	Sole i polimorfy związku tetracyklinowego
BRPI0919447A2 (pt)	2015-12-15	derivados do ácido 1-amino-2-ciclobutiletilborônico
HK1253355A1 (zh)	2019-06-14	含有馬西替坦的治療組合物
DK2315756T3 (da)	2014-10-13	1,2,5-oxadiazoler som inhibitorer af indolamin-2,3-dioxygenase
DK3192520T3 (da)	2019-05-27	Terapeutiske midler til reducering af niveauerne af parathyreoideahormon
DK2504005T3 (da)	2014-01-13	Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
BR112012001325A2 (pt)	2017-05-02	tratamento de distúrbios do fígado com inibidaores de pi3k
BRPI0918824A2 (pt)	2015-12-08	elemento magnetocalórico
DK2346509T3 (da)	2020-08-03	Inhalation af levofloxacin til at reducere lungeinflammation
DK2755481T3 (da)	2020-06-15	Anvendelse af alginatoligomerer til at forøge virkningerne af svampemidler
DK2249866T3 (da)	2012-10-22	Anvendelse af et acetylsalicylsyresalt til behandlingen af virusinfektioner
DK2421537T3 (da)	2015-06-22	Pyrazolylaminopyridiner som inhibitorer af FAK
DK3005986T3 (da)	2021-11-22	Infusion af lægemidler
DK2358714T3 (da)	2012-08-20	Alkylcyclohexylethere af dihydrotetraazabenzoazulener
DK2411009T3 (da)	2013-06-24	Terapeutiske anvendelser af quinazolindionderivater
DK2117564T3 (da)	2011-10-17	Anvendelse af chitosaner til forøgelse af neglevæksthastigheden
DK2462098T3 (da)	2013-11-25	Fremgangsmåde til fremstillingen af derivater af 1-(2-halobiphenyl-4-yl)-cyclopropancarboxylsyre
DK2143429T5 (da)	2014-06-30	Anvendelse af cilastatin til reduktion af nephrotoksicitet af forskellige forbindelser
DK2231640T3 (da)	2012-07-16	Beta-aminosyrederivater til behandling af diabetes
BRPI0920845A2 (pt)	2018-05-22	uso de análogos de ácido heteroaromáticos contendo enxofre
DE602008005536D1 (de)	2011-04-28	Herstellung von MnB12H12
IT1403587B1 (it)	2013-10-31	Composizione per il trattamento di disordini metabolici
ATE526966T1 (de)	2011-10-15	Flüssige formulierungen von salzen von 4-ä2-(4- methylphenylsulfanyl)phenylüpiperidin